On June 3, 2026, Cabaletta Bio unveiled promising new clinical data that could mark a turning point in the treatment of autoimmune diseases.

The company shared new results from its RESET clinical trials for myositis, lupus, and systemic sclerosis—studies evaluating a groundbreaking CAR-T cell therapy designed to “reset” the immune system and achieve lasting remission without ongoing immune-suppressing medications.

The therapy, known as rese-cel (formerly CABA-201), showed encouraging progress. In the myositis cohort, patients demonstrated major clinical improvement without the use of additional immunomodulatory therapies.

“These early results demonstrate what’s possible when innovative science meets deep commitment to patients,” said Dr. Andrew Heaton, Chief Scientific Officer at Cure JM Foundation. “CAR-T therapy has the potential to transform how we treat autoimmune disease, moving us from lifelong immune suppression toward immune reset and true remission. We’re encouraged by this progress and remain dedicated to accelerating research that brings these breakthroughs to our patients.”

These early findings point to a future in which CAR-T cell therapy could deliver lasting, drug-free remission for people living with autoimmune diseases, including juvenile myositis.

As we celebrate America’s 250th year, we also celebrate the power of a community united by hope. Breakthroughs like these do not happen by accident—they are made possible through research, innovation, and the unwavering support of families and advocates.

Every dollar raised through Walk Strong Across America helps advance the research that is bringing us closer to safer treatments, lasting remission, and ultimately a cure for juvenile myositis. Join families across all 50 states and help keep this progress moving forward.

Sign Up Here To Represent Your State